Curis to Release Fourth Quarter and Year-End 2019 Financial Results and Hold Conference Call on March 19, 2020

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter and full-year 2019 financial results on Thursday, March 19, 2020, after the close of US markets

LEXINGTON, Mass., March 12, 2020 /PRNewswire/ -- Curis, Inc., (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter and full-year 2019 financial results on Thursday, March 19, 2020, after the close of US markets. Management will host a conference call on the same day at 4:30 p.m. ET.

To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the ‘Investors’ section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in combination with venetoclax in a Phase 1 clinical study in patients with DLBCL. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis’ website at www.curis.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/curis-to-release-fourth-quarter-and-year-end-2019-financial-results-and-hold-conference-call-on-march-19-2020-301021373.html

SOURCE Curis, Inc.


Company Codes: NASDAQ-NMS:CRIS
MORE ON THIS TOPIC